RET rearrangements are present in about 10%–20% of thyroid cancers and 1%–3% of non-small cell lung cancer (NSCLC) cases, making routine testing for RET fusions at diagnosis advisable (Nacchio et al., 2022; Li et al., 2019). Here, RET is linked to non-small cell lung carcinoma.